Our objective was to study the effects of pneumonia (cumulative incidence, 25%), diarrhea (29%), umbilical infection (14%), and umbilical hernia (15%) on BW and height gains during the first 3 mo of life. Female dairy calves (n = 410) born from January to December 1990 in 18 commercial herds in New York state were used. Average daily gains during the 1st, 2nd, and 3rd mo were 374, 596, and 719 g, respectively; average gain was 565 g during the 3-mo period. Average monthly height gains during the 1st, 2nd, and 3rd mo were 4.4, 5.6, and 5.7 cm, respectively. Use of multiple linear regression, with farms treated as random effects, indicated that treated, verified pneumonia was associated with a reduction in average daily gain of 66 g and that failure of passive transfer reduced average daily gain by 48 g during the 1st mo. During the 2nd mo, neither disease nor failure of passive transfer affected average daily gain. During the 3rd mo, each additional week of pneumonia reduced average daily gain by 14 g, and umbilical infection reduced average daily gain by 96 g. Each additional week of diagnosed pneumonia reduced total BW gain during the first 3 mo by 0.8 kg. Similarly, each week of pneumonia reduced total height gain by 0.2 cm and failure of passive transfer by 0.9 cm. Prevention of chronic pneumonia and umbilical infection may improve average daily gain of calves.
The objective of this study was to evaluate the effect of dietary starch content and monensin (MON) on metabolism of dairy cows during early lactation. Before parturition, primiparous (n=21) and multiparous (n=49) Holstein cows were fed a common controlled-energy close-up diet with a daily topdress of either 0 or 400mg/d monensin. From d 1 to 21 postpartum, cows were fed a high-starch (HS; 26.2% starch, 34.3% neutral detergent fiber, 22.7% acid detergent fiber, 15.5% crude protein) or low-starch (LS; 21.5% starch, 36.9% neutral detergent fiber, 25.2% acid detergent fiber, 15.4% crude protein) total mixed ration with a daily topdress of either 0mg/d monensin (CON) or 450mg/d monensin (MON), continuing with prepartum topdress assignment. From d 22 through 63 postpartum, all cows were fed HS and continued with the assigned topdress treatment until d 63. Cows fed HS had higher plasma glucose and insulin and lower nonesterified fatty acids (NEFA) than cows fed LS during d 1 to 21 postpartum. Cows fed LS had elevated early-lactation β-hydroxybutyrate (BHBA) compared with cows fed HS. Cows fed HS had greater insulin resistance and increased plasma haptoglobin in the early lactation period. There was no effect of MON on postpartum plasma NEFA. Cows fed MON had higher plasma glucose compared with CON cows, which was driven by a MON × parity interaction in which primiparous cows fed MON had greater plasma glucose concentrations than cows fed CON. Cows fed MON had lower plasma BHBA compared with CON, which was contributed to by a MON × parity interaction in which primiparous cows fed MON had lower BHBA concentrations than CON. Starch treatment had no effect on overall liver triglyceride content. Primiparous cows fed MON had increased liver triglyceride content compared with CON primiparous cows, and multiparous cows fed MON had decreased liver triglyceride content compared with CON cows. Multiparous cows fed LS with MON had higher liver glycogen content than multiparous cows fed the LS without MON, with no effect of MON treatment for multiparous cows fed HS. There was no effect of starch or MON treatment on liver capacity to oxidize propionate to CO2, and effects of starch on gluconeogenesis were not significant. Cows fed MON tended to have greater capacity to convert propionate to glucose than CON. Supplementation with MON increased the ratio of glucose to CO2, which indicated that cows fed MON had a greater propensity to convert propionate to glucose. Overall, cows fed more propiogenic diets in early lactation (high starch or monensin) exhibited improved energy metabolism during early lactation.
The effects of temperature and colostrum components on specific gravity in bovine colostrum were investigated. Thirty-nine first milking colostrum samples were collected from Holstein cows. The samples were assayed for alpha-tocopherol, fat, protein, total solids, and IgG. The concentrations of total solids, total protein, total IgG, and fat in colostrum were 26.6, 12.5, 3.7, and 9.4 g/100 g, respectively. A range of 1.8 to 24.7 micrograms/ml for alpha-tocopherol was measured in the colostrum samples. Specific gravity of the colostrum was measured using a hydrometer in increments of 5 degrees C from 0 to 40 degrees C. Specific gravity explained 76% of the variation in colostral total IgG at a colostrum temperature of 20 degrees C. The regression model was improved only slightly with the addition of protein, fat, and total solids. The model for samples at 20 degrees C was IgG (milligrams per milliliter) = 958 x (specific gravity) - 969. Measurement of specific gravity at variable temperatures necessitated inclusion of temperature in the model for estimation of IgG. Inclusion of the other components of colostrum into the model slightly improved the fit. The regression model for samples at variable temperatures was as follows: IgG (milligrams per milliliter) = 853 x (specific gravity) + .4 x temperature (Celsius degrees) - 866.
The objective of this study was to evaluate the effect of postpartum dietary starch content and monensin supplementation throughout the periparturient period and into early lactation on production performance of dairy cows during early lactation. Prior to parturition, primiparous (n=21) and multiparous (n=49) Holstein cows were fed a common controlled-energy close-up diet with a daily topdress of either 0 or 400mg/d monensin. From d 1 to 21 postpartum, cows were fed a high-starch (HS; 26.2% starch, 34.3% NDF, 22.7% ADF, 15.5% CP) or low-starch (LS; 21.5% starch, 36.9% NDF, 25.2% ADF, 15.4% CP) total mixed ration with a daily topdress of either 0mg/d of monensin or 450mg/d monensin (MON), continuing with prepartum topdress treatment assignment. From d 22 through 63 postpartum, cows were fed HS and continued with their assigned daily topdress. Interactions of starch content and MON supplementation were not significant for any of the variables measured. Cows fed HS from wk 1 to 3 postpartum had higher early-lactation milk yields (starch × week interaction) compared with LS cows, but HS cows also had lower percentages of milk fat, true protein, lactose, and total solids during the same period, resulting in similar yields of energy-corrected milk (ECM) between starch treatments. Cows fed HS had higher early-lactation dry matter intake (DMI; starch × week interaction) and lost less body condition score during wk 1 to 3, contributing to improved energy balance postpartum. No effect of starch treatment was observed on apparent total-tract dry matter or starch digestibilities assessed during d 18 to 19 (±2) postpartum, although cows fed the LS diet had greater apparent total-tract NDF digestibility compared with cows fed the HS diet. Cows fed MON had higher DMI and higher milk yields during the first 9 wk of lactation. However, all cows had similar yields of ECM because of trends for lower milk fat content during early lactation. In part because of similar yields of ECM between these treatments and higher DMI for cows fed MON, ECM per DMI during the first 9 wk of lactation was not affected by MON treatment. There was no effect of MON treatment on apparent total-tract dry matter, NDF, or starch digestibilities. Overall, cows fed more propiogenic diets in early lactation (HS or MON) had increased milk yield and DMI during the immediate postpartum period, indicating that diets with greater propiogenic capacity do not have detrimental effects on early-lactation DMI.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.